EXEL vs. UTHR
EXEL (Exelixis, Inc.) and UTHR (United Therapeutics Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, EXEL returned 21.91%/yr vs 17.67%/yr for UTHR. At a 0.36 correlation, their price movements are largely independent.
Performance
EXEL vs. UTHR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EXEL achieves a 21.22% return, which is significantly higher than UTHR's 12.05% return. Over the past 10 years, EXEL has outperformed UTHR with an annualized return of 21.91%, while UTHR has yielded a comparatively lower 17.67% annualized return.
EXEL
- 1D
- -0.69%
- 1M
- 3.59%
- YTD
- 21.22%
- 6M
- 29.97%
- 1Y
- 27.17%
- 3Y*
- 40.39%
- 5Y*
- 18.25%
- 10Y*
- 21.91%
UTHR
- 1D
- 0.10%
- 1M
- -5.79%
- YTD
- 12.05%
- 6M
- 10.52%
- 1Y
- 90.80%
- 3Y*
- 33.49%
- 5Y*
- 24.97%
- 10Y*
- 17.67%
EXEL vs. UTHR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
EXEL Exelixis, Inc. | 21.22% | 31.62% | 38.81% | 49.56% | -12.25% | -8.92% | 13.90% | -10.42% | -35.30% | 103.89% |
UTHR United Therapeutics Corporation | 12.05% | 38.09% | 60.46% | -20.93% | 28.70% | 42.35% | 72.33% | -19.12% | -26.39% | 3.15% |
Correlation
The correlation between EXEL and UTHR is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.33 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Apr 17, 2000 | 0.36 |
Fundamentals
EXEL:
$14.20B
UTHR:
$25.77B
EXEL:
$3.00
UTHR:
$27.00
EXEL:
17.72
UTHR:
20.22
EXEL:
0.31
UTHR:
0.66
EXEL:
6.22
UTHR:
8.21
EXEL:
7.34
UTHR:
4.37
EXEL:
$2.38B
UTHR:
$3.17B
EXEL:
$1.70B
UTHR:
$2.74B
EXEL:
$991.79M
UTHR:
$1.75B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EXEL vs. UTHR — Risk / Return Rank
EXEL
UTHR
EXEL vs. UTHR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EXEL | UTHR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.25 | ||
| Sortino ratioReturn per unit of downside risk | -3.11 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.49 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.08 | 8.58 | -7.49 |
| Martin ratioReturn relative to average drawdown | 2.61 | 20.13 | -17.51 |
Loading charts...
Drawdowns
EXEL vs. UTHR - Drawdown Comparison
The maximum EXEL drawdown since its inception was -97.38%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for EXEL and UTHR.
Loading charts...
Drawdown Indicators
| EXEL | UTHR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.38% | -93.18% | -4.20% |
Max Drawdown (1Y)Largest decline over 1 year | -25.16% | -10.64% | -14.52% |
Max Drawdown (3Y)Largest decline over 3 years | -25.34% | -33.00% | +7.66% |
Max Drawdown (5Y)Largest decline over 5 years | -36.12% | -33.00% | -3.12% |
Max Drawdown (10Y)Largest decline over 10 years | -57.20% | -55.56% | -1.64% |
Current DrawdownCurrent decline from peak | -0.69% | -8.51% | +7.82% |
Average DrawdownAverage peak-to-trough decline | -71.03% | -35.31% | -35.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.42% | 4.53% | +5.89% |
Volatility
EXEL vs. UTHR - Volatility Comparison
Exelixis, Inc. (EXEL) has a higher volatility of 9.96% compared to United Therapeutics Corporation (UTHR) at 5.01%. This indicates that EXEL's price experiences larger fluctuations and is considered to be riskier than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EXEL | UTHR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.96% | 5.01% | +4.95% |
Volatility (6M)Calculated over the trailing 6-month period | 25.50% | 25.94% | -0.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.27% | 47.55% | -7.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 37.16% | 35.08% | +2.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 44.47% | 35.06% | +9.41% |
Dividends
EXEL vs. UTHR - Dividend Comparison
Neither EXEL nor UTHR has paid dividends to shareholders.
Financials
EXEL vs. UTHR - Financials Comparison
This section allows you to compare key financial metrics between Exelixis, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EXEL vs. UTHR - Profitability Comparison
EXEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported a gross profit of 0.00 and revenue of 610.81M. Therefore, the gross margin over that period was 0.0%.
UTHR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a gross profit of 648.10M and revenue of 781.50M. Therefore, the gross margin over that period was 82.9%.
EXEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported an operating income of 251.34M and revenue of 610.81M, resulting in an operating margin of 41.2%.
UTHR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported an operating income of 325.80M and revenue of 781.50M, resulting in an operating margin of 41.7%.
EXEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exelixis, Inc. reported a net income of 210.47M and revenue of 610.81M, resulting in a net margin of 34.5%.
UTHR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a net income of 274.90M and revenue of 781.50M, resulting in a net margin of 35.2%.
Frequently Asked Questions
EXEL and UTHR have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
EXEL has higher volatility (9.96%) compared to UTHR (5.01%). In terms of maximum drawdown, EXEL dropped -97.38% vs UTHR's -93.18%.
UTHR currently has the higher Sharpe Ratio (1.92 vs 0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EXEL and UTHR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer